Live NH election results:
Business

Abiomed stock falls 31 percent after the Danvers company says it’s under federal investigation

Shares of Abiomed Inc. plunged by nearly one-third on the Nasdaq stock exchange Thursday after the Danvers company said it is the subject of a federal investigation.

In documents filed with the Securities and Exchange Commission, the cardiac device maker disclosed it has received a subpoena from the US attorney’s office seeking files related to the labeling and marketing of its Impella 2.5 heart pump.

Advertisement

“We are in the process of responding to the subpoena and intend to cooperate fully,” Abiomed said in the filing.

Abiomed’s shares closed Thursday at $13.61, down $6.21, or 31.33 percent, on the Nasdaq.

Robert Weisman

Robert Weisman can be reached at weisman@globe.com.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.